$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma
TEL AVIV, Israel and RALEIGH, N.C., Oct. 19, 2026 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that its partner, the University of Oklahoma (OU), has received $2.9 million in funding from the...